Cowen analyst Doug Schenkel lowered his price target on Exact Sciences following its slight Q2 miss, but he said his buy thesis remains firmly intact. He said the slight miss was due to a compliance issue and changes in salesforce initiatives, but the revenue target remains intact. Schenkel maintained his Outperform rating but lowered his price target to $65 from $85 on Exact Sciences shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.